论文部分内容阅读
目的分析低分子肝素钙治疗早期子痫前期的临床效果。方法选择2012年4月~2014年11月期间于我院进行分娩的子痫早期病人为研究对象。采用随机数字表法分为观察组和对照组各37例,对照组给予常规解痉、降压治疗,观察组根据临床表现每天两次皮下注射低分子肝素钙。比较两组子痫前期患者妊娠延长天数,产后出血量,新生儿体质量及Apgar评分。结果观察组明显延长了妊娠天数,与对照组比较,差异有统计学意义(t=6.696,P<0.01):且产后24小时出血量与对照组相比,无明显增加,差异无统计学意义(t=1.344,P>0.05);新生儿体质量明显大于对照组,差异有统计学意义(t=4.408,P<0.01)。观察组新生儿1分钟和5分钟Apgar评分≥7的例数明显高于对照组,差异有统计学意义(χ~2=11.236,9.946,P<0.01)。结论低分子肝素钙可用于子痫前期患者的治疗,可以延长孕龄,提高新生儿体质量,且不会使产后出血量增加,因此值得临床应用。
Objective To analyze the clinical effect of low molecular weight heparin on early stage of preeclampsia. Methods The patients with early eclampsia who delivered in our hospital from April 2012 to November 2014 were selected as the study objects. The random number table was divided into observation group and control group, 37 cases in each group. The control group was given conventional antispasmodic and antihypertensive treatment. The observation group received twice daily subcutaneous injection of low molecular weight heparin calcium according to the clinical manifestations. The number of days of pregnancy extension, postpartum hemorrhage, neonatal body weight and Apgar score were compared between the two groups. Results The observation group significantly prolonged the number of gestational days, compared with the control group, the difference was statistically significant (t = 6.696, P <0.01), and the 24-hour postpartum hemorrhage volume compared with the control group had no significant increase, the difference was not statistically significant (t = 1.344, P> 0.05). The newborn’s weight was significantly higher than that of the control group (t = 4.408, P <0.01). The number of newborns in observation group 1 minute and 5 minutes Apgar score ≥ 7 was significantly higher than the control group, the difference was statistically significant (χ ~ 2 = 11.236,9.946, P <0.01). Conclusion Low molecular weight heparin can be used in the treatment of patients with preeclampsia, which can prolong the gestational age and improve the quality of newborn, and will not increase the amount of postpartum hemorrhage. Therefore, it is worthy of clinical application.